Masking of Receptors for Sheep Erythrocytes on Human T-Lymphocytes by Sera From Breast Cancer Patients
            2

Whitehead, Robert H.; Roberts, Gary P.; Thatcher, J.; Teasdale, C.; Hughes, L. E.

doi:10.1093/jnci/58.6.1573

Cited by 15 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously shown that sera from breast cancer patients can a inhibit E-rosette formation by normal T-lymphocytes (Whitehead et al, 1976(Whitehead et al, , 1977. In this study we found significant inhibitory action of the serum from patients with carcinoma of the stomach, colon, or rectum on normal lymphocytes, as compared with the sera of healthy controls.…”

Section: Serum Inhibition Studiessupporting

confidence: 47%

“…This factor is related to tumour presence but its source and nature are not known. In an earlier study (Whitehead et al, 1977) we have demonstrated some evidence that this factor is a tumour disintegration product comprising cell debris or cell membrane fragments which bind to E-receptor sites of Tlymphocytes.…”

Section: Serum Inhibition Studiesmentioning

confidence: 95%

“…After the incubation, lymphocytes were washed twice in isotonic saline and E-rosetting carried out. From the E-rosette percentage after incubation in autologous serum or cancer serum, percentage inhibition of normal T-lymphocytes was calculated (Whitehead et al, 1977). VIABILITY The viability of lymphocytes was checked using dye exclusion methods.…”

Section: Serum Inhibitionmentioning

confidence: 99%

See 2 more Smart Citations

Significance of tumour mass on T-lymphocyte levels in patients with gastrointestinal cancer.

Shukla¹,

Whitehead²,

Hughes³

1979

Gut

View full text Add to dashboard Cite

SUMMARY The relationship between tumour load and immunity in gastrointestinal cancer has been studied by sequential comparison in patients whose tumour has been removed and those whose tumour was found to be inoperable. Total 29 March 1979 in patients' serum, indicating the presence of an E-receptor masking factor in the sera. In view of the role of T-lymphocytes in immune surveillance, the persistence of such a serum factor after treatment would continue to depress 'functional' T-lymphocyte levels and might contribute to the spread of cancer. If the serum factor is a tumour-related product, it should disappear from the serum after successful treatment. We have therefore investigated

show abstract

Section: Serum Inhibition Studiessupporting

confidence: 47%

Section: Serum Inhibition Studiesmentioning

confidence: 95%

Section: Serum Inhibitionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of tumour mass on T-lymphocyte levels in patients with gastrointestinal cancer.

Shukla¹,

Whitehead²,

Hughes³

1979

Gut

View full text Add to dashboard Cite

show abstract

“…While it was repeatedly shown that p43-positive lymphocytes were mainly detected in patients with early stages (in situ cancer or T1N0), other authors described a depressed lymphocyte re-sponse in patients with early stage disease [5,6]. It was further found that p43 placental ferritin (PLF) has immuno-suppressive activity [7,8].…”

Section: Introductionmentioning

confidence: 99%

Immunosuppression by breast cancer associated p43-effect of immunomodulators

Rosén¹,

Ausch²,

Reiner³

et al. 1996

Breast Cancer Res Tr

View full text Add to dashboard Cite

It has been previously shown that p43- a breast cancer associated antigen-has immunosuppressive properties. The present study was carried out in order to elucidate the pathomechanisms of immunosuppression in breast cancer patients influenced by the expression of p43. Lymphocytes were cultured from blood of 29 women with benign lesions in the breast as well as from 41 female patients with breast cancer. Lymphocyte stimulation was performed by addition of Concanavalin (Con A) in cultures with lymphocytes alone (CONLYM) or in lymphocytes incubated with p43 (CONAg). In other series immunomodulation was tried by addition of indomethacin (INDLYM, INDAg), levamisole (LEVLYM, LEVAg), or interleukin-2 (ILLYM, ILAG). In breast cancer patients, addition of p43 significantly inhibited the activation of lymphocyte proliferation by Con A compared to women with benign tumors. The addition of indomethacin or levamisole did not influence this inhibitory effect of p43 in breast cancer patients. Contrary to these observations, addition of IL-2 resulted in increased proliferation of lymphocytes from patients with benign as well as malignant tumors, which was inhibited after addition of p43. Analysis of the correlation of the immunosuppressive properties of p43 in correlation with prognostic factors for breast cancer showed evidence for a stronger activity of p43 in early stage tumors (i.e. smaller than 2 cm, lymph node negative, histologic grading GI), confirming previous observations of a higher expression of p43 in early stages of breast cancer.

show abstract

E-rosette inhibition and tumour recurrence in early breast cancer

Haffejee

Webster

Paterson

et al. 1983

Journal of British Surgery

View full text Add to dashboard Cite

The relationship of serum blocking activity and susceptibility to tumour recurrence using E-rosette inhibition by normal allogenic lymphocytes was evaluated before and after operation in 20 patients with early breast cancer. Preoperative serum inhibition levels did not predict recurrent tumour. The mean postoperative inhibition in patient with recurrence was significantly greater than in those without recurrence. Postoperative testing only in a group of 124 patients showed that the development of local tumour recurrence was preceded by significantly greater inhibition of E-rosetting than occurred in patients without recurrence. The application of a threshold level of serum inhibition of 15 per cent distinguishes patients who are unlikely to develop tumour recurrence over a 4-year follow-up period. Serial measurements of serum inhibition at 6-monthly intervals over 2 years did not add to the predictive value of this test.

show abstract

Masking of Receptors for Sheep Erythrocytes on Human T-Lymphocytes by Sera From Breast Cancer Patients 2

Cited by 15 publications

References 0 publications

Significance of tumour mass on T-lymphocyte levels in patients with gastrointestinal cancer.

Significance of tumour mass on T-lymphocyte levels in patients with gastrointestinal cancer.

Immunosuppression by breast cancer associated p43-effect of immunomodulators

E-rosette inhibition and tumour recurrence in early breast cancer

Contact Info

Product

Resources

About